CureVac to cut 30% of workforce as GSK buys rights to make flu, covid shots (NASDAQ:CVAC)
2024-07-03
CureVac N.V. (NASDAQ:CVAC) to cut its workforce by 30% as part of a restructuring initiative, as GSK (NYSE:GSK) acquires full rights to develop, manufacture and commercialize globally mRNA candidate vaccines for influenza and COVID-19, for €1.45 billion plus royalties. The new agreement extends CureVac’s (CVAC) cash runway into 2028, asContinue Reading